Previous issue | Volume 92 | ESPE2019 | Next issue

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

Card image cap
The theme of this year’s meeting is Variety and Variation in Paediatric Endocrinology. Join us in Vienna to explore the diversity we encounter in our discipline and the care that we have to exercise when using the term “normality”. Whilst gaining an update on the latest treatments, clinical best practice and cutting edge research in the field of paediatric endocrinology.

Poster Category 1

GH and IGFs

hrp0092p1-72 | GH and IGFs | ESPE2019

Diagnostic Value of Random Serum Growth Hormone (GH), IGF-I and IGFBP-3 Concentrations for the Diagnosis of Growth Hormone Deficiency (GHD) in Patients Below One Year of Life

Ballerini María Gabriela , Braslavsky Débora , Freire Analía Verónica , Keselman Ana , Rodríguez María Eugenia , Altube Mercedes , Scaglia Paula Alejandra , Bergadá Ignacio , Ropelato María Gabriela

GHD diagnosis in neonates and infants is a challenge owing to the fact that GH pharmacological stimulation tests (GHST) are not approved at this age. In a retrospective study, we found that a random GH<6.5 µg/L confirmed GHD diagnosis in neonates with clinical suspicion of GHD with high diagnostic accuracy (1). The accuracy of GH and its surrogates of action have not been set for infants with current standardized immunoassays.Objective</...

hrp0092p1-73 | GH and IGFs | ESPE2019

Influence of Birth Parameters on Growth Response and Metabolic Effects of Growth Hormone (GH) Therapy in GH-deficient Children and Adolescents

Witkowska-Sedek Ewelina , Ruminska Malgorzata , Kucharska Anna M. , Majcher Anna , Pyrzak Beata

Introduction: Growth depends on growth hormone (GH) secretion and on individual sensitivity to its action. The effects of birth parameters on growth and metabolic status are well documented in small-for-gestational-age children, but in children with GH deficiency those associations are not clear. Taking into account that GH-deficient children are not a homogenic group of patients, the importance of an individual approach to GH doses and the assessment of the e...

hrp0092p1-74 | GH and IGFs | ESPE2019

Recombinant GH Treatment in Child with Pseudopseudohypoparathyroidism Associated with Growth Hormone Deficiency

Karachaliou Feneli , Skarakia Nikitas , Mitrogiorgou Marina , Simatou Aristophania , Peppa Melpomeni , Papaevangelou Vassiliki

Background: Pseudopseudohypoparathyroidism (PPHP) is a rare variant of pseudohypoparathyroidism (PHP) type I, with typical anatomical abnormalities known as Albright's hereditary osteodystrophy (AHO)(short stature, brachydactyly particularly involving metacarpals and metatarsals, round face, stocky build, ectopic ossifications and a number of possible associated defects), but with normal calcium, phosphate and PTH levels and normal response to exogenous PT...

hrp0092p1-75 | GH and IGFs | ESPE2019

Impact of -202 IGFBP-3 Promoter Polymorphism on Growth Responses in Korean Children with Idiopathic Short Stature

Hwang II Tae , Yi Kyung Hee , Kim Eun Young , Yang Seung

Purpose: Our previous study showed no correlation between -202 A/C IGFBP-3 promoter polymorphism and Δheight SDS in children with growth hormone deficiency. We investigated the influences of the -202 IGFBP-3 polymorphism on 1-year follow-up outcomes of GH treatment in Korean children with ISS.Methods: Data was obtained from 81 children with idiopathic short stature (peak serum growth hormone (GH) ≥ 7.0 ng/mL b...

hrp0092p1-76 | GH and IGFs | ESPE2019

The Diagnostic Value of Serum Acid-labile Subunit (ALS) Alone and in Combination with IGF-1 and IGFBP-3 in the Diagnosis of Idiopathic Growth Hormone Deficiency (iGHD)

Chen Jiajia , Ertl Diana- Alexandra , Andreas Gleiss , Janu Dominik , Sagmeister Susanne , Raimann Adalbe , Gong ChunXiu , Haeusler Gabriele

Background: The acid-labile subunit (ALS) is the crucial third player in the tertiary complex for its function of prolonging the half-life of the IGF1-IGFBP3 binary complexes. IGF1 and IGFBP3 are routinely determined during the diagnostic work-up for growth hormone deficiency (GHD). The aim of the study is to evaluate the relevance of serum ALS as an additional biomarker, alone or in combination with IGF1 and IGFBP3, in the diagnosis of GHD.<p class="abste...

hrp0092p1-77 | GH and IGFs | ESPE2019

Severe IGF-I Deficiency in Children with Normal Growth Hormone (GH) Secretion and Excluded GH Insensitivity – is it Really Idiopathic Short Stature?

Joanna Smyczynska , Urszula Smyczynska , Andrzej Lewinski , Maciej Hilczer

According to current recommendations, children with height SDS <-3.0, normal growth hormone (GH) peak in stimulation tests (stimGH) and severe IGF-I deficiency (IGFD) may be diagnosed with primary IGFD and treated with recombinant IGF-I. The need for direct confirmation of GH insensitivity is a matter of discussion. On the other hand, children born small for gestational age (SGA) with no catch-up growth are qualified to GH therapy despite normal GH secretion. The fact that...

hrp0092p1-78 | GH and IGFs | ESPE2019

Premature Infants Born Small by Gestational Age: the Role of Insulin-like Growth Factor-1 in the Regulation of Postnatal Growth

Kovalenko Tatyana , Yuditskiy Anton , Petrova Irina

The role of insulin-like growth factor-1 (IGF-1) in the regulation of growth of children with intrauterine growth is currently being discussed, but the final point of view has not been achieved.Aim: to study the effect of IGF-1 in the dynamics of postnatal growth of premature infants with SGA in the first 5 years of life.Material and Methods: The prospective study included prematurity with SGA (gro...

hrp0092p1-79 | GH and IGFs | ESPE2019

The experience of Pain in Children with Growth Hormone Deficiency and Psychosocial Correlates: Preliminary Data from a Longitudinal Prospective Study

Bettini Alessandra , Teodori Caterina , Maffei Francesca , Ciofi Daniele , Stagi Stefano

Background: Pain represents one of the most stressful experiences for children undergoing medical therapies (Kortesluoma, 2008), but is under represented in literature for what concerns pediatric endocrinology. Children consider Injections one of the most painful, frighteningand distressing procedures (Fassler, 1985). The treatment for patients with Growth Hormone Deficiency requires daily subcutaneous injection, performed by parents or patients themselves. Th...

hrp0092p1-80 | GH and IGFs | ESPE2019

Clinical Characteristics, Puberty Pattern and Adult or Near-adult-height Data in a Group of Patients with Growth Failure due to Severe Primary IGF-1 Deficiency (GROWPATI Study)

Stoupa Athanasia , Lorraud Christine , Flechtner Isabelle , Viaud Magali , Pinto Graziella , Samara-Boustani Dinane , Thalassinos Caroline , Brioude Frédéric , Netchine Irène , Amselem Serge , Legendre Marie , Polak Michel

Background: Severe primary insulin-growth factor-1 (IGF-1) deficiency (SPIGF1D) is a rare cause of growth retardation. Diagnostic criteria include age- and sex-dependent low basal IGF-1 levels (<2.5th percentile), height ≤ -3SDS, absence of growth hormone deficiency and of any secondary causes of growth failure.Objectives: Description of pubertal onset and growth spurt, data on adult or near-adult-he...

hrp0092p1-81 | GH and IGFs | ESPE2019

Effect of Recombinant Growth Hormone Therapy on Retinal Nerve Fiber in Children with Idiopathic Growth Hormone Deficiency

Çinici Emine , Orbak Zerrin

Introduction: Growth hormone (hGH) and/or growth factors are thought to play a role in the pathogenesis of diabetic retinopathy. Increased treatment of human growth hormone (hGH) in children rise questions concerning the safety of GH replacement therapy on ophtalmic changes. Adverse effects of hGH treatment (pseudotumor cerebri, papilloedema, retinal changes mimicking diabetic retinopathy, neovascularization) have been reported in some papers. In this study, i...

hrp0092p1-82 | GH and IGFs | ESPE2019

Positive Impact on Adherence Through Educational Activities of the Argentina´s Patient Support Program in Children with low Adherence to Treatment with Recombinant Growth Hormone (easypod applicator)

Assefi Aria Reza , Chareca Cinthia , Roca Fernanda , Rubstein Adrian , Ayala Luciana Celis , Von Schulz Hausmann Cristian

Background: One of the main concerns in patients with growth disorders is to achieve optimal adherence to growth hormone (GH) treatment. For this it is important to identify patients with low adherence to treatment and to evaluate actions to improve it.The Merck Patient Support Program (PSP) carried out educational actions aimed at patients with low adherence and their parents, to raise their awareness of the importance of good adherence...

hrp0092p1-83 | GH and IGFs | ESPE2019

Identification of Novel Recessive IGFALS Mutations and INSR Variant in an Obese Korean Boy

Kim Yoo-Mi , Lim Han Hyuk , Kim Seon Young

IGFALSgene is located in chromosome 16p13.3 encoding acid labile subunit which binds insulin-like growth factors (IGFs) to increase their half-life and vascular localization. The biallelic defect of this gene leads to acid-labile subunit deficiency characterized by postnatal growth retardation, insulin resistance, delayed puberty, and no growth hormone deficiency. A 5-year-old-boy was referred to as low IGF-1 and cortisol level. He presented with obesity and growth re...